Press release
Adalimumab Biosimilar Market Growth and Restrain Factors Analysis Report
According to the latest research by InsightAce Analytic, the global Adalimumab Biosimilar Market Size is estimated to grow at the CAGR of 23.0% during the forecast period for 2025-2034.
Request For Free Sample Pages:
https://www.insightaceanalytic.com/request-sample/1058
A biosimilar is a biological product that closely resembles an already approved reference biologic in terms of safety, purity, and effectiveness. One notable example is Adalimumab, which the U.S. Food and Drug Administration (FDA) first approved in December 2002 as the first fully human monoclonal antibody. Adalimumab is widely prescribed for the treatment of several autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, psoriasis, ulcerative colitis, and more. Marketed under brand names such as Humira and Exemptia, it works by targeting and binding to tumor necrosis factor-alpha (TNF-α)-a substance in the body that triggers inflammation in autoimmune disorders.
The global adalimumab biosimilars market is predicted to expand rapidly during the forecast period, owing to a rise in the number of arthritis among the global population and a growth in the number of skin disorders, which would lead to an increase in demand for Adalimumab. According to the Worl Health Organisation (WHO), skin problems are the most common cause of impairment to human health. It is estimated that over 900 million people worldwide suffer from skin problems at any given moment. Many of these skin conditions cause permanent disfigurement, stigma, and impairment, and adequately treating them has become a significant priority for health organizations worldwide.
In this context, the biosimilar adalimumab has emerged as a promising therapy option for chronic skin illnesses such as eczema. This aspect can significantly increase the size of the global adalimumab biosimilar market throughout the forecast period. Furthermore, launching new biosimilars will decrease medicine prices worldwide, resulting in strong market demand. During the forecast period, this is expected to boost the expansion of the worldwide adalimumab biosimilar market.
North America is anticipated to be the major contributor to the Adalimumab Biosimilar market over the forecast years. According to the American Autoimmune Related Diseases Association, over 50 million Americans have an autoimmune disease. Furthermore, the annual healthcare costs for treating these disorders are nearly USD 100 billion. This, combined with an ageing population, will likely offer North America the highest share of the global adalimumab biosimilar market throughout the forecast period. In addition, the Asia Pacific Adalimumab Biosimilar market is expected to grow significantly during the forecast period. The rising elderly population and increased governmental and private investment in pharmaceuticals drive the Asia-Pacific market. In addition, increasing investments in medical research are also projected to fuel the market.
Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1058
Major market players operating in the Adalimumab Biosimilar market include
Amgen, Pfizer, Celltrion Healthcare Co., Ltd., Sandoz International GmbH, LG Life Sciences, Mochida Pharmaceutical, Fresenius Kabi, Kyowa Hakko Kirin, and Momenta Pharmaceuticals.
Recent collaborations and agreements in the market:
• In June 2022, Sandoz stated that the European Medicines Agency (EMA) has accepted for regulatory consideration the application for high concentration formulation 100 mg/mL (HCF) of its biosimilar Hyrimoz® (adalimumab). All indications covered by the reference medicine* are included in the application, including rheumatoid arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and uveitis.
• In April 2022, Celltrion Healthcare Canada Limited announced the introduction of Yuflyma®, a biosimilar of Humira® that is high-concentration (100 mg/mL), low-volume, citrate-free, and latex-free (adalimumab). Yuflyma® is a biosimilar of Humira® containing adalimumab with a high-concentration, low-volume, and citrate-free formulation. Celltrion Healthcare Canada Limited continues to be devoted to a patient-centric strategy in order to assure access to novel, high-quality biologics in Canada.
• In Feb 2022, Pfizer Inc. announced that the FDA has accepted the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADATM (adalimumab-afzb) as an interchangeable biosimilar to Humira® for evaluation (adalimumab). Positive topline results from the REFLECTIONS B538-12 trial, which investigated numerous switches between ABRILADA and its reference medication, Humira, both of which were taken with methotrexate in adult patients with moderate to severe rheumatoid arthritis, backed up the PAS (RA).
Get Specific Chapter/Information From The Report:
https://www.insightaceanalytic.com/customisation/1058
Market Segments
Global Adalimumab Biosimilar Market, by Application, 2025-2034 (Value US$ Mn)
• Rheumatoid Arthritis
• Juvenile Idiopathic Arthritis
• Psoriatic Arthritis
• Crohn's Disease
• Ankylosing Spondylitis
• Ulcerative Colitis
• Psoriasis
Global Adalimumab Biosimilar Market, by Distribution Channel, 2025-2034 (Value US$ Mn)
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Direct Distribution Channels
Global Adalimumab Biosimilar Market, by Region, 2025-2034 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Adalimumab Biosimilar Market, by Country, 2025-2034 (Value US$ Mn)
• U.S.
• Canada
Europe Adalimumab Biosimilar Market, by Country, 2025-2034 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Adalimumab Biosimilar Market, by Country, 2025-2034 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Adalimumab Biosimilar Market, by Country, 2025-2034 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Adalimumab Biosimilar Market, by Country, 2025-2034 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa
Get More Information: @
https://www.insightaceanalytic.com/report/global-adalimumab-biosimilar-market/1058
About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.
Contact Us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adalimumab Biosimilar Market Growth and Restrain Factors Analysis Report here
News-ID: 4138575 • Views: …
More Releases from Insightace Analytic Pvt Ltd.
Abdominal Aorta Stent Grafts Market Size, Share and Trends Analysis Report 2025- …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Abdominal Aorta Stent Grafts Market- by Product Type (Polymer and Metal), End Users (Hospitals, Ambulatory Surgical Centers and Specialty Clinics), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the global Abdominal Aorta Stent Grafts market is is expected to record a CAGR of 4.9% during a forecast…
Wide Bandgap Semiconductor Market Report- Expansive Coverage on the Profit Sourc …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Wide Bandgap Semiconductor Market - (By Material (Silicon Carbide (SiC) Substrate, Gallium Nitride (GaN) Substrate, Aluminum Nitride (AIN) Substrate, Others), By Application (Power Discrete Devices, RF Devices, Optoelectronic Devices)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global Wide Bandgap Semiconductor Market is valued at US$…
Vendor Neutral Archive (VNA) Market Future Trends and Scope Analysis Report
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Vendor Neutral Archive (VNA) Market - (By Deployment Model (On-Premise VNA, Cloud-Based VNA), By Vendor Type (Independent Software Vendors (ISVs), PACS Vendors, Infrastructure Vendors), By Imaging Type (Radiology VNAs, Cardiology VNAs, Pathology VNAs), By End User (Hospitals, Diagnostic Imaging Centers, Ambulatory Care Centers, Research and Academic Institutes)), Trends, Industry Competition Analysis, Revenue and Forecast To…
RNA Therapy Clinical Trials Market Report on the Untapped Growth Opportunities i …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global RNA Therapy Clinical Trials Market Size, Share & Trends Analysis Report By By Modality (RNA interference, Antisense therapy, Messenger RNA, and Oligonucleotide, non-antisense, non-RNAi), By Phase ((Phase I, Phase II, Phase III, & Phase IV)), By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological), Region, Market Outlook And Industry Analysis 2034"
The global RNA Therapy Clinical Trials…
More Releases for Adalimumab
Adalimumab Biosimilar Market Report and Forecast 2024-2032
Global Adalimumab Biosimilar Market Outlook
The adalimumab biosimilar market is expected to grow at a CAGR of about 17.60% in the forecast period of 2024-2032, driven by the rising incidence of rheumatoid arthritis, especially amongst the rapidly growing geriatric population.
Adalimumab Biosimilar: Introduction
Adalimumab biosimilars are biologic medical products highly similar to the reference product, Humira, which is used to treat autoimmune diseases. These biosimilars offer comparable efficacy, safety, and quality at a…
Adalimumab Biosimilar Market Size, Share, Trends 2024-2032
The adalimumab biosimilar market is witnessing substantial growth, driven by the rising incidence of rheumatoid arthritis and an increasing geriatric population. Adalimumab, a popular biologic for treating various inflammatory diseases, has seen a surge in biosimilar counterparts due to their cost-effectiveness and expanding applications. The market is expected to grow at a CAGR of about 17.60% from 2024-2032, reflecting significant opportunities for industry players.
Get a Free Sample Report with Table…
Adalimumab Market Insights, Forecast to 2031
"Adalimumab Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Adalimumab market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Adalimumab industry, providing stakeholders with a nuanced perspective on market dynamics.
Furthermore, the…
Adalimumab Market Size, Status & Forecast 2024
Global Adalimumab Market: Overview
Adalimumab, with a trade name of Humira and Exemptia, is an anti-TNF drug used for treating rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, psoriasis and ulcerative colitis. Adalimumab usually binds with tumor necrosis factor-alpha (TNFα). When a TNFα binds to a TBFα receptors, it results in an inflammatory response to autoimmune disease. Adalimumab, by binding to a TNFα, lowers the chances of inflammatory response.
View Report @ http://www.transparencymarketresearch.com/adalimumab-market.html
Adalimumab, which…
Adalimumab Market - Forecasts from 2014 to 2020
Adalimumab is a biologic TNF inhibiting anti-inflammatory medication which is a patented medicine of Abbott Biotechnology Ltd. Jochen G. Salfeld et al invented the product and trade names for the product are Exemptia and Humira. Humira stands for "human monoclonal antibody in rheumatoid arthritis". Humira targets and acts as building block for TNF-alpha production, and lowering inflammation. TNF blockers with HUMIRA, has adverse affects on the immune system which…
Increasing Research and Penetration of Adalimumab Biosimilars Boosts Demand for …
The impending patent expiration has resulted in the sluggish growth rate of the adalimumab market in Latin America. The entry of biosimilars has further aggravated the market’s concerns. Transparency Market Research (TMR) pegs the valuation of the Latin America adalimumab market at US$994.8 mn in 2014. Expanding at a weak CAGR of 0.4% from 2015 to 2023, the market is forecast to reach US$1,186.4 mn by the end of 2023.
Download…
